# A Study to Predict Gefitinib' s Efficacy for Lung Cancer by Plasma Free Nucleic Acids EGFR Gene Mutation Test

> **NCT02738684** · — · UNKNOWN · sponsor: **Southwest Hospital, China** · enrollment: 100 (estimated)

## Conditions studied

- Lung Adenocarcinoma

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT02738684
- **Lead sponsor:** Southwest Hospital, China
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-04
- **Primary completion:** 2018-01
- **Final completion:** 2018-01
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2016-04-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02738684

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02738684, "A Study to Predict Gefitinib' s Efficacy for Lung Cancer by Plasma Free Nucleic Acids EGFR Gene Mutation Test". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02738684. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*